Abstract
Idiopathic inflammatory myopathies (IIM) are acquired systemic autoimmune diseases affecting multiple organs as well as muscle. Though prednisolone is the first-choice treatment, evidence-based treatment policy for IIM have not been fully established. Therefore, we analyzed the treatments given to IIM patients and examined the complications that affected treatment strategies and the outcomes. We analyzed 81 IIM patients (26 men and 55 women) undergone muscle biopsy from January 2008 to December 2017.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
